Literature DB >> 9336301

Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels.

R Gebhardt1, G Beckers, F Gaunitz, W Haupt, D Jonitza, S Klein, L Scheja.   

Abstract

CCl4-induced cirrhosis of rats was used for studying the influence of L-ornithine-L-aspartate (OA) on hyperammonemia. OA given to cirrhotic rats (2 g/kg daily) for 2 wk slightly increased net body weight and led to a significant increase in plasma urea levels and a decrease in plasma ammonia levels. Serum concentrations of glutamate, glutamine and arginine decreased significantly. In the livers of the OA-treated rats the activities of carbamoylphosphate synthetase I and arginase increased by 30 and 40%, respectively, approaching normal levels. No change in the activities of the other urea cycle enzymes as well as of glutamate dehydrogenase, glutaminase and glutamine synthetase was found. The negative correlation between glutamine synthetase activity and plasma ammonia levels reported previously for cirrhotic rats (Gebhardt and Reichen, Hepatology 20:684-691, 1994) was corroborated for cirrhotic animals not treated with OA, but was no longer apparent in OA-treated cirrhotic rats. Despite this improvement, plasma ammonia levels still varied considerably reflecting the variable accessibility and activities of glutamine synthetase in cirrhotics. Cultured hepatocytes from the two groups of rats showed a similar stimulation of urea production by addition of ammoniumacetate and/or OA to Hanks' buffered salt solution. In Williams medium E, however, the hepatocytes from the OA group produced significantly more urea than those from controls. These results suggest that treatment of cirrhotic rats with OA considerably improves urea production favoring the detoxification of ammonia that, however, is still limited by the severe alterations in liver architecture that are not influenced by OA in a 2-wk period.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336301

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

Authors:  Avinash Kumar; Gangarao Davuluri; Rafaella Nascimento E Silva; Marielle P K J Engelen; Gabrie A M Ten Have; Richard Prayson; Nicolaas E P Deutz; Srinivasan Dasarathy
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

2.  L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.

Authors:  C Rose; A Michalak; P Pannunzio; G Therrien; G Quack; G Kircheis; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-06       Impact factor: 3.584

3.  Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats.

Authors:  Abul K Najmi; K K Pillai; S N Pal; M Akhtar; M Aqil; M Sharma
Journal:  Indian J Pharmacol       Date:  2010-12       Impact factor: 1.200

Review 4.  L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.

Authors:  Roger F Butterworth
Journal:  Can J Gastroenterol Hepatol       Date:  2019-04-28

5.  Precipitating Factors and Treatment Outcomes of Hepatic Encephalopathy in Liver Cirrhosis.

Authors:  Nandu S Poudyal; Sitaram Chaudhary; Sudhamshu Kc; Bidhan N Paudel; Bhupendra K Basnet; Amrendra Mandal; Paritosh Kafle; Baikuntha Chaulagai; Azad Mojahedi; Mukesh S Paudel; Barun Shrestha; Vijay Gayam
Journal:  Cureus       Date:  2019-04-02

6.  Combined Effects of Amino Acids in Garlic and Buna-Shimeji (Hypsizygus marmoreus) on Suppression of CCl4-Induced Hepatic Injury in Rats.

Authors:  Yusuke Yamaguchi; Yushi Hirata; Takeshi Saito; Hitomi Kumagai
Journal:  Foods       Date:  2021-06-27

Review 7.  L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Ee Teng Goh; Caroline S Stokes; Sandeep S Sidhu; Hendrik Vilstrup; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2018-05-15

Review 8.  Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.

Authors:  Gerald Kircheis; Stefan Lüth
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.